Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

~~Claims 1-4 (canceled)~~

Claim 5 (currently amended): A compound of the formula (V):



or its pharmaceutically acceptable salt thereof, wherein:

B1

(a) B, D and E are independently O~~, S, NR^7 or CR^7R^8~~;

(b) G is OR^{11}, $NR^{11}R^{12}$ or SR^{11};

(c) R^1, R^2, R^3, R^4, R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, ~~a residue of~~ a natural or synthetic amino acid, ~~a residue of~~ a natural or synthetic carbohydrate or XR^9 (wherein X = O, S or NR^{10}); and

(d) ~~alternatively, one or more of R^1 and R^2, R^2 and R^3, R^3 and R^4, R^4 and R^5, or R^5 and R^6, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and~~

~~(e)~~ each R^7, R^8, R^9, R^{10}, R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl,

heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, ~~a residue of~~ a natural or synthetic amino acid or ~~a residue of~~ a natural or synthetic carbohydrate

~~optionally in a pharmaceutically acceptable carrier~~.

Claims 6-22 (canceled)

Claim 23 (currently amended): A ~~method~~ pharmaceutical composition for the treatment ~~or~~ ~~prophylaxis~~ of an inflammatory disorder in a host comprising ~~administering~~ an effective treatment amount of a compound according to claim 5 optionally in a pharmaceutically acceptable carrier or diluent.

Claim 24 (currently amended): A ~~method~~ pharmaceutical composition for the treatment ~~or~~ ~~prophylaxis~~ of an autoimmune disorder in a host comprising administering an effective treatment amount of a compound according claim 5 optionally in a pharmaceutically acceptable carrier or diluent.

Claim 25 (currently amended): A compound of formula:



or its pharmaceutically acceptable salt thereof.

Claim 26 (currently amended): A ~~method~~ pharmaceutical composition for the treatment ~~or~~ ~~prophylaxis~~ of an inflammatory disorder in a host comprising ~~administering~~ an effective treatment amount of a compound of formula:



or its pharmaceutically acceptable salt thereof, wherein:

(a) B, D and E are independently O~~, S, NR^7 or CR^7R^8~~;

(b) G is OR^{11}, $NR^{11}R^{12}$ or SR^{11};

(c) R^1, R^2, R^3, R^4, R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, ~~a residue of~~ a natural or synthetic amino acid, ~~a residue of~~ a natural or synthetic carbohydrate or XR^9 (wherein X = O, S or NR^{10}); and

B1

(d) ~~alternatively, one or more of R^1 and R^2, R^2 and R^3, R^3 and R^4, R^4 and R^5, or R^5 and R^6, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and~~

(~~e~~) each R^7, R^8, R^9, R^{10}, R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, ~~a residue of~~ a natural or synthetic amino acid or ~~a residue of~~ a natural or synthetic carbohydrate

optionally in a pharmaceutically acceptable carrier in combination ~~or alternation~~ with other anti-inflammatory agents.

Claim 27 (currently amended): The ~~method~~ pharmaceutical composition of ~~claims 23-26~~ claim 23, 24, or 26, wherein the host is a human.

Claim 28 (currently amended): The ~~method~~ pharmaceutical composition of ~~claims~~ claim 23, 24, or 26, ~~or 27,~~ wherein the compound is in the form of a dosage unit.

Claim 29 (currently amended): The ~~method~~ pharmaceutical composition according to claim 28, wherein the dosage unit contains 7 to 3000 mg of the compound.

Claim 30 (currently amended): The ~~method~~ pharmaceutical composition according to claim 28, wherein the dosage unit contains 70 to 1400 mg of the compound.

Claim 31 (currently amended): The ~~method~~ pharmaceutical composition according to claim 28, wherein the dosage unit contains 50-500 mg of the compound.

Claim 32 (currently amended): The ~~method~~ pharmaceutical composition according to claim 28, wherein the dosage unit is a tablet or capsule.

Claim 33 (currently amended): The ~~method~~ pharmaceutical composition according to claim 26, wherein the anti-inflammatory agent is selected from the group consisting of heparin, frusemide, ranitidine, an agent that effects respiratory function, immunosuppressive agents, IV gamma globulin, troleandomycin, cyclosporin (Neoral), methotrexate, FK-506, gold compounds, platelet activating factor (PAF), leukotriene-D_4-receptor antagonists), Ziflo (zileuton), leukotriene C_1 or C_2 antagonists and inhibitors of leukotriene synthesis, and an inducible nitric oxide synthase inhibitor.

Claim 34 (currently amended): The ~~method~~ pharmaceutical composition of claim 26, wherein the anti-inflammatory agent is selected from the group consisting β_2-adrenergic agonist (β agonists).

Claim 35 (currently amended): The ~~method~~ pharmaceutical composition of claim 34, wherein the β agonist is selected from the group consisting of albuterol (salbutamol, Proventil, Ventolin), terbutaline, Maxair (pirbuterol), Serevent (salmeterol), epinephrine, metaproterenol (Alupent, Metaprel), Brethine (Bricanyl, Brethaire, terbutaline sulfate), Tornalate (bitolterol), isoprenaline, ipratropium bromide, bambuterol hydrochloride, bitolterol meslyate, broxaterol, carbuterol hydrochloride, clenbuterol hydrochloride, clorprenaline hydrochloride, efirmoterol fumarate, ephedra (source of alkaloids),

ephedrine (ephedrine hydrochloride, ephedrine sulfate), etafedrine hydrochloride, ethylnoradrenaline hydrochloride, fenoterol hydrochloride, hexoprenaline hydrochloride, isoetharine hydrochloride, isoprenaline, mabuterol, methoxyphenamine hydrochloride, methylephedrine hydrochloride, orciprenaline sulphate, phenylephrine acid tartrate, phenylpropanolamine (phenylpropanolamine polistirex, phenylpropanolamine sulphate), pirbuterol acetate, procaterol hydrochloride, protokylol hydrochloride, psuedoephedrine (psuedoephedrine polixtirex, psuedoephedrine tannate, psuedoephedrine hydrochloride, psuedoephedrine sulphate), reproterol hydrochloride, rimiterol hydrobromide, ritodrine hydrochloride, salmeterol xinafoate, terbutaline sulphate, tretoquinol hydrate and tulobuterol hydrochloride.

B1

Claim 36 (currently amended): The ~~method~~ pharmaceutical composition according to claim 26, wherein the anti-inflammatory agent is selected from the group consisting of a corticosteroid, antihistamine (H_1 receptor antagonists), xanthines and methylxanthines, anticholinergic agents (antimuscarinic agents), and phosphodiesterase inhibitors.

Claim 37 (new): A pharmaceutical composition for the treatment of an inflammatory disorder in a host comprising an effective treatment amount of a compound of formula:



or its pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 38 (new): A pharmaceutical composition for the treatment of an inflammatory disorder in a host comprising an effective treatment amount of a compound of formula:



or a pharmaceutically acceptable salt thereof; optionally in a pharmaceutically acceptable carrier, in combination with another anti-inflammatory agent.

Claim 39 (new): The pharmaceutical composition of claim 37 or 38, wherein the compound is in the form of a dosage unit.

B1

Claim 40 (new): The pharmaceutical composition of claim 39, wherein the dosage unit contains 7 to 3000 mg of the compound.

Claim 41 (new): The pharmaceutical composition of claim 39, wherein the dosage unit contains 70 to 1400 mg of the compound.

Claim 42 (new): The pharmaceutical composition of claim 39, wherein the dosage unit contains 50-500 mg of the compound.

Claim 43 (new): The pharmaceutical composition of claim 39, wherein the dosage unit is a tablet or capsule.

Claim 44 (new): The pharmaceutical composition of claim 38, wherein the anti-inflammatory agent is selected from the group consisting of heparin, frusemide, ranitidine, an agent that effects respiratory function, immunosuppressive agents, IV gamma globulin, troleandomycin, cyclosporin (Neoral), methotrexate, FK-506, gold compounds, platelet activating factor (PAF), leukotriene-D_4-receptor antagonists), Ziflo (zileuton), leukotriene C_1 or C_2 antagonists and inhibitors of leukotriene synthesis, and an inducible nitric oxide synthase inhibitor.

Claim 45 (new): The pharmaceutical composition of claim 38, wherein the anti-inflammatory agent is selected from the group consisting β_2-adrenergic agonist (β agonists).

Claim 46 (new): The pharmaceutical composition of claim 45, wherein the β agonist is selected from the group consisting of albuterol (salbutamol, Proventil, Ventolin), terbutaline, Maxair (pirbuterol), Serevent (salmeterol), epinephrine, metaproterenol (Alupent, Metaprel), Brethine (Bricanyl, Brethaire, terbutaline sulfate), Tornalate (bitolterol), isoprenaline, ipratropium bromide, bambuterol hydrochloride, bitolterol meslyate, broxaterol, carbuterol hydrochloride, clenbuterol hydrochloride, clorprenaline hydrochloride, efirmoterol fumarate, ephedra (source of alkaloids), ephedrine (ephedrine hydrochloride, ephedrine sulfate), etafedrine hydrochloride, ethylnoradrenaline hydrochloride, fenoterol hydrochloride, hexoprenaline hydrochloride, isoetharine hydrochloride, isoprenaline, mabuterol, methoxyphenamine hydrochloride, methylephedrine hydrochloride, orciprenaline sulphate, phenylephrine acid tartrate, phenylpropanolamine (phenylpropanolamine polistirex, phenylpropanolamine sulphate), pirbuterol acetate, procaterol hydrochloride, protokylol hydrochloride, psuedoephedrine (psuedoephedrine polixtirex, psuedoephedrine tannate, psuedoephedrine hydrochloride, psuedoephedrine sulphate), reproterol hydrochloride, rimiterol hydrobromide, ritodrine hydrochloride, salmeterol xinafoate, terbutaline sulphate, tretoquinol hydrate and tulobuterol hydrochloride.

B1

Claim 47 (new): The pharmaceutical composition of claim 38, wherein the anti-inflammatory agent is selected from the group consisting of a corticosteroid, antihistamine (H_1 receptor antagonists), xanthines and methylxanthines, anticholinergic agents (antimuscarinic agents), and phosphodiesterase inhibitors.

Claim 48 (new): The pharmaceutical composition of any one of claims 37 or 38, wherein the host is a human.